Obermatt

West Pharmaceutical Services

NYQ:WST · US9553061055
Life Sciences Tools & ServicesLarge

360

80
EV / EBIT13
Price / Owner Earnings22
Owner Earnings Yield61
Dividend Yield85
Price/Sales15
EV / Gross Profit11
Price/Book17
Return on Capital93
Cash Return on Capital87
Return on Equity86
EBIT Margin77
Gross Profitability75
Cash Conversion32
Accruals34
Owner Earnings Margin75
Sales growth65
Profit Growth86
Long-Term EPS Growth65
Owner Earnings Growth78
Reinvestment10
Price momentum69
Debt load82
Refinancing37
Debt Payback100
Liquidity100
Analyst ratings71
Opinion Changes50
Price Target Upside29
Market mood77
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

West Pharmaceutical Services generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeNYSE
Founded1923
Employees4,401
ISINUS9553061055
Last UpdateApr 2, 2026
Themes
Biomedical EngineeringPackaging ServicesInjection MoldingOphthalmology

Description

West Pharmaceutical Services, Inc. operates as a global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The company’s prod…

Analysis

Hope premium

West Pharmaceutical Services, Inc. carries what we call a hope premium: an average business trading at an ambitious price. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 50.4× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 19% yearly growth; analysts expect 13%. The gap between price and consensus is worth watching: demanding expectations.

The trajectory is solid and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
96
2023202420252026

All-time high

100

Jan 2023

All-time low

19

Aug 2024

Average rank

77

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
15
31
13
31
Price/Earnings
12
18
18
24
Price/Book
17
23
9
14
Dividend Yield
85
82
83
79
Value (overall)
25
28
29
26

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare West Pharmaceutical Services with its peers
Niagen Bioscience
NAQ:NAGE
71
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Inotiv
NAQ:NOTV
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Aptargroup
NYQ:ATR
75
CountryUSA
IndustryContainers & Packaging
SizeLarge
Full Stock Analysis →
Sotera Health
NSQ:SHC
59
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Avantor
NYQ:AVTR
13
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Lifecore Biomedical
NSQ:LFCR
12
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →